Figure 4E shows mean LC3 puncta per cell exhibited little to no change in preclinical PD model stages when compared to control (19 ± 0.9, 18 ± 0.8, 20 ± 0.8 puncta per cell for control, 24 h, and 5 d), but showed a statistically significant increase in the end-stage PD model (22 ± 0.9 puncta per cell, p < 0.05). Here, MAP1LC3A is linked to Parkinson disease.